OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Neurology is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Lymphatic propagation of α-synuclein	499
Microglia, spreaders of Aβ seeds	443
Transmembrane protein interacts with α-synuclein to confer risk of PD	299
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	288
Ventricular enlargement caused by aducanumab	285
Brain stimulation aids walking after spinal injury	267
Getting specific: targeting Fc receptors in myasthenia gravis	240
Neural cell state shifts and fate loss in ageing and age-related diseases	232
Global synergistic actions to improve brain health for human development	209
Reply to ‘Perils and pitfalls of near-death experience research’	207
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	206
Refining oxytocin therapy for autism: context is key	206
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	196
NODDI reveals brain microstructural changes in multiple sclerosis	186
Disease-specific modifications of tau protein	177
Continuous levodopa production by an artificial enzyme	176
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	166
The impact of rare genetic variants on Alzheimer disease	164
Spinal muscular atrophy treatment in utero	161
Nir Giladi (1955–2024)	141
The Digitized Memory Clinic	138
SEQUINS — a new initiative to address disparities in neurology	134
Mitochondrial DNA instability in Huntington disease	128
Study reveals new ALS risk genes	127
TREM2 mediates phagocytosis in glioblastoma	124

Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	124
Imperatives and co-benefits of research into climate change and neurological disease	121
Microglia subset associated with high-grade glioma	117
The role of the gut microbiota in multiple sclerosis	110
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	106
Ultrasound lets gene therapy into the brain	102
Brain volume is associated with cognition in MS	101
Role for endogenous retrovirus in FTD	100
Menopause influences tau pathology	98
Amyloid plaques: hotspots for microglial turnover	97
Neurological care for LGBT+ people	97
The challenges of anti-tau therapeutics in Alzheimer disease	95
Psychosis-causing lesions mapped to a hippocampal circuit	95
Neuroinflammation predicts cognitive decline in FTD	93
Implications of AD plasma and PET biomarker discordance	91
MRI-based deep learning for TLE diagnosis	90
Brain imaging illuminates cognitive impairment in multiple sclerosis	85
Diversity, equity and inclusion in neurology	85
APOE ε4 influences Parkinson disease progression	84
First trials test targeting of α-synuclein for Parkinson disease	82
Author Correction: Viral pathogens increase risk of neurodegenerative disease	82
Parkinson disease pathology can originate in the kidney	79
Precision neuroimmunology in multiple sclerosis — the horizon is near	78
Gene therapy for seizures in focal cortical dysplasia	75
Management of freezing of gait — mechanism-based practical recommendations	74
α-Synuclein pathology as a target in neurodegenerative diseases	74
Challenges of combining multimodal data in assessment of people with traumatic brain injury	74
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	71
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	69
Evidence for altered astrocyte function in Duchenne muscular dystrophy	68
New IDEAS about amyloid, race and dementia disparities	67
Food is brain medicine — relevance and translation to neurology	65
Glymphatic dysfunction in PD clinical progression	64
Neurosteroids alleviate seizures in rats	64
Thalamic inflammation — a therapeutic target for brain injury?	63
A new biological classification for Parkinson disease	62